"We value the engagement of our shareholders and take their feedback seriously," said Matthew Lipman, Chief Executive Officer of Capstone. "This FAQ is intended to help the market better understand ...

Kiniksa Pharmaceuticals leverages ARCALYST as it is a first-in-class FDA-approved treatment for recurrent pericarditis, driving recurring revenue and strong growth. Q3 FY2025 ARCALYST revenue was $180 ...

Stride, Inc. LRN continues to deliver robust margin growth. In third-quarter fiscal 2025, the company reported a robust performance with adjusted EBITDA rising 40% year over year to a record $168.3 ...

Management outlines progress converting platform scale into profitability while reducing long-term dilution risk. NEW YORK CITY, NEW YORK / ACCESS Newswire / January 28, 2026 / Capstone Holding Corp. ...